In 1965, a group of scientists from Montreal arrived on Easter Island, also known as Rapa Nui, to collect soil samples. This was the inauspicious beginning of an extraordinary and unpredictable series of events that make up a wonderful biomedical story. Distinct achievements and discoveries that shaped this story, in which I had the good fortune to be a protagonist, were recognized with a Lasker Award in 2012 and now in 2017.
Joe's initial experiments were with cyclosporin A and FK506. Although these two drugs had little to no effect on growth of our laboratory yeast strain, Joe characterized the yeast FK506-binding protein (FKBP) encoded by the gene he named FPR1. Rao later gave us some rapamycin, which Joe found arrested yeast cells in the G1 phase of the cell cycle-the same effect the drug had on T cells! This gave us confidence that our risky idea might have merit. Moreover, Joe found that FK506 antagonized rapamycin toxicity (structurally similar, FK506 and rapamycin competitively bind FKBP) and that strains in which he had deleted the FPR1 gene were fully resistant to rapamycin. This suggested that an FKBP-rapamycin complex was the active, toxic agent in the cell, rather than rapamycin alone. To identify the target of the FKBP-rapamycin complex, Joe isolated several spontaneous rapamycin-resistant mutants. At this stage, Joe was furiously working around the clock to finish the characterization of his mutants before returning to New York City to complete clinical rotations. By early December 1990, he knew that the mutants were defective in the FPR1 gene, as expected based on his earlier experiments, or that they harbored a dominant mutation in at least one other unknown gene. The December 2 entry from Joe's lab notebook shows his progress in characterizing two resistant mutants (R1 and R17) defective in the unknown gene(s). As indicated in his notes, he wondered whether the mutations were in the same gene or in different genes. Knowing there was at least one new gene (''gene X''), he began listing candidate gene names (FAP, FIP, RAT, TFR, TOR, PAF, PIF, RAR) that fit the yeast three-letteracronym nomenclature convention. As is now well known, we chose TOR, for target of rapamycin. I liked the name TOR because it was easy to say and remember. Joe had a more romantic reason for favoring it. In German, TOR (das Tor) means ''gate,'' and at the time, we viewed TOR as the entry to the cell cycle, much like the gates in the wall that formerly encircled Basel were the entry into the city. Joe was not deterred by the fact that the masculine form of the German noun Tor (der Tor) means ''fool.'' To resolve the issue of one versus two new genes, Joe put the diploid from an R1 Â R17 cross on sporulation medium (''spo plates'') to eventually dissect apart the spores and determine whether the mutations were linked or segregated independently. He managed to complete this experiment, among many others, before leaving Basel in late December. He showed that the rapamycin resistance-conferring mutations in R1 and R17 were unlinked and thus in two distinct genes: TOR1 and TOR2. This was the discovery of TOR, at least as genetic loci in the yeast genome. We published Joe's findings in Science on August 23, 1991. Coincidentally, on that same day, Stuart Schreiber published a paper in Cell, showing that the phosphatase calcineurin is a common target of cyclosporin A and FK506.
What did the two TOR genes encode? To answer this question, two very talented students in the lab, Jeannette Kunz and later Stephen Helliwell, cloned and sequenced the TOR genes. This was much more difficult than anticipated because the TOR genes are among the largest in yeast and were thus under-represented in the size-fractioned genomic libraries we had generated for cloning purposes (Hall, 2016 , Mol. Biol. Cell 27, 2804 -2806 . The sequencing revealed that the two TORs were novel, highly similar kinases and also that Joe's rapamycin-resistanceconferring mutations were missense mutations that, as shown later, prevented FKBP-rapamycin binding to TOR without otherwise affecting TOR activity. Rapamycin acts by forming a complex with FKBP/FPR1, which in turn directly binds and inhibits TOR. The mammalian TOR (mTOR) gene was cloned shortly thereafter by several other groups, including Stuart Schreiber's, David Sabatini in Solomon Snyder's, and Robert Abraham's groups, and was shown to encode a kinase similar to yeast TOR, hence the name mTOR. Schreiber's laboratory subsequently demonstrated that a reconstituted mTOR variant containing a missense mutation analogous to one of our yeast TOR mutations conferred rapamycin resistance in mammalian cells. Thus, the mode of action of rapamycin was conserved, as presumed by Joe and Rao when they initiated the project.
What is the cellular role of the TOR kinases other than being the target of rapamycin? Answering this question took several years and led to our most gratifying and possibly most important discovery (Hall, 2016, Mol. Biol. Cell 27, 2804-2806). We originally thought that the role of TOR was to control the cell cycle. This model was based on the cell cycle arrest we observed upon TOR inhibition. However, during a fateful seminar I gave in Vienna in late 1993 to members of the Institute of Molecular Pathology, including the cell cycle expert Kim Nasmyth and his group, I was disabused of this notion. As I learned in Vienna, our kinase did not fit neatly into what was then known about cell cycle control. This view was reinforced as we began to discover that TOR controlled processes related to macromolecular synthesis and unrelated to the cell division cycle. We then began to consider that the true role of TOR was to control cell growth (increase in cell size/ mass), rather than cell division (increase in cell number), in response to nutrients. This was a particularly important conceptual advance because it cast our hitherto confusing results in a new light. We suddenly understood our results. It was also a paradigm shift because cell growth was not thought to be actively controlled. To the students of today, it probably seems odd that we once thought cell growth is a spontaneous, passively controlled process that just happens when building blocks are available. Over the subsequent years, we and others showed that TOR activates several anabolic processes and inhibits catabolic processes, confirming that TOR controls mass accumulation and thereby cell growth. In 2000, we proposed that TOR is a central controller of cell growth. The misleading cell cycle arrest we had observed was an indirect consequence of a cell growth defect.
The next major problem was to elucidate the mechanism by which TOR controls cell growth. Jeannette Kunz had earlier knocked out the two TOR genes, finding that the two TORs are not functionally equivalent. More precisely, she had found that loss of TOR1 had no effect on cell viability, whereas knockout of TOR2 was lethal. When she knocked out both TOR1 and TOR2, cells were not viable, but the cells displayed a G1 arrest not observed upon loss of TOR2 alone. This suggested that TOR1 has one function, while TOR2 has two functions, one of which is redundant with the single TOR1 function. Further analyses, by several excellent students and postdocs, including Stephen Helliwell, Nic Barbet, Anja Schmidt, Marc Bickle, Thomas Beck, Estela Jacinto, José Luis Crespo, Tobias Schmelzle, Martin Dietmar, Vittoria Zinzalla, Alexandre Soulard, and Mitsugu Shimobayashi, revealed that the two TOR ''functions'' are two distinct signaling pathways. TOR1 signals via an effector pathway that activates protein synthesis and other processes. TOR2 can substitute for TOR1 in this pathway, but also has an independent function, signaling via a different effector pathway to control the actin cytoskeleton. These observations provided a logical conceptual framework-TOR signals via two pathways to integrate temporal and spatial control of cell growth-but we still did not understand the molecular basis of this signaling complexity. To investigate the complexity of TOR signaling, Robbie Loewith, an undaunted cold-tolerant Canadian postdoc, and my long-term technician Wolfgang Oppliger Section of December 2, 1990, entry from Joe Heitman's lab notebook, the first appearance of the name TOR.
entered the cold room to purify the TOR proteins from yeast. The idea was to develop a purification scheme that would be sufficiently gentle to allow co-purification and thereby identification of TOR interacting proteins. This was difficult because we did not know whether TOR even had interacting proteins and, thus, what the appropriate purification scheme might be. Robbie's biochemical characterization, also aided by Stephan Wullschleger, revealed that the TORs are part of two structurally and functionally distinct complexes, which we named TORC1 and TORC2. Either TOR1 or TOR2 assembles into TORC1, but only TOR2 assembles into TORC2. Robbie then showed that the two TORCs correspond to the two previously identified TOR signaling pathways, thereby providing a molecular basis for the complexity of TOR signaling. Estela Jacinto, Pazit Polak, Nadine Cybulski, Asami Hagiwara, Aaron Robitaille, Raú l Durá n, Marion Cornu, and Verena Albert in our laboratory and others showed that the two complexes are structurally and functionally conserved in mammals, where they are known as mTORC1 and mTORC2. David Sabatini, in particular, played a key role in elucidating the mammalian TOR complexes.
Over the course of the last 15 years, it has become apparent that mTOR is implicated in a wide variety of diseases in addition to allograft rejection, including cancer and diabetes, and in aging. This, in turn, has spawned a great deal of activity in the pharmaceutical industry to develop new drugs that target the mTOR signaling network. Such drugs may restore normal life to even more patients. Thus, due to an amazing turn of events, rapamycin has had impact in medicine, fundamental biology, and the pharmaceutical industry. It all started with an unknown scientist bending over to pick up a handful of dirt in a faraway land and time.
